MedTrace Logo

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

NCT00116636 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-05-01

No results posted yet for this study

Summary

Expected Enrollment: 40 patients

Study Start Date: June 2005

Study Objectives:

* To conduct a pilot study to assess the safety, tolerability, and antiviral activity of Kaletra 400/100 mg taken twice a day (bid) in antiretroviral (ARV)-naïve HIV-infected patients at Week 48

Primary Objectives:

* To determine the proportion of patients with HIV RNA \<400 copies/mL at weeks 24 and 48
* To determine the proportion of patients with HIV RNA \< 50 at weeks 24 and 48
* To elucidate the specific adverse event (AE) profile of Kaletra single agent therapy

Secondary Objectives:

* To assess the proportion of patients below the limit of quantification (LOQ) at each visit. Patients will be observed at baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48.
* To determine the time to HIV RNA reaching \<400 and \<50 copies/mL
* To determine the time to virologic failure
* To assess change from baseline at each visit for HIV RNA and CD4 count at weeks 4, 8, 12, 24 and 48.
* To assess changes in genotype from baseline to time of confirmed virologic failure (2 consecutive HIV RNA measurements \>400 copies/mL after suppressing to \<400 copies/mL) or at time of treatment intensification.
* To characterize changes in lipid and triglyceride concentrations over time and the effect of treatment with appropriate drugs (fibrate or statin, if necessary) on these elevations.
* To evaluate the safety and tolerability of subjects through 48 weeks of drug exposure.
* To describe virologic response following intensification in Kaletra single agent virologic failures

Conditions

  • HIV Infections

Interventions

DRUG

Kaletra

Sponsors & Collaborators

  • Therapeutic Concepts

    lead OTHER

Principal Investigators

  • Joseph C. Gathe, M.D. · Therapeutic Concepts, P.A.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116636 on ClinicalTrials.gov